[go: up one dir, main page]

PE20060877A1 - Compuestos y composiciones como inhibidores de la kinasa proteica - Google Patents

Compuestos y composiciones como inhibidores de la kinasa proteica

Info

Publication number
PE20060877A1
PE20060877A1 PE2006000097A PE2006000097A PE20060877A1 PE 20060877 A1 PE20060877 A1 PE 20060877A1 PE 2006000097 A PE2006000097 A PE 2006000097A PE 2006000097 A PE2006000097 A PE 2006000097A PE 20060877 A1 PE20060877 A1 PE 20060877A1
Authority
PE
Peru
Prior art keywords
alkyl
thazol
trifluoromethyl
phenyl
methyl
Prior art date
Application number
PE2006000097A
Other languages
English (en)
Inventor
Taebo Sim
Nathanael Schiander Gray
Yi Liu
Shuli You
Qiang Ding
Songchun Jiang
Pamela A Albaugh
Xia Wang
Qiong Zhang
Pingda Ren
Hyun Soo Lee
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of PE20060877A1 publication Critical patent/PE20060877A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE n ES 0-4; R1 ES H, ALQUILO C1-C4, (ARILO C6-C10)-ALQUILO(C1-C4), ENTRE OTROS; R2 ES H, ALQUILO C1-C6; R3 ES H, ALQUILO C1-C6; R4 ES HALO, ALQUILO C1-C6, ALCOXILO C1-C6, ENTRE OTROS; R15 ES DE PREFERENCIA 3-TRIFLUOROMETIL-BENZOIL-AMINO. SON COMPUESTOS PREFERIDOS: ACIDO 2-(3-DIETILAMINOPROPILAMINO)-TIAZOL-5-CARBOXILICO[2-METIL-5-(3-TRIFLUOROMETIL-BENZOILAMINO)-FENIL]-AMIDA; ACIDO 2-{6-[4-(2-HIDROXIETIL)-PIPERAZI-1-NIL]-2-METILPIRIMIDI-4-NILAMINO}-TIAZOL-5-CARBOXILICO[2-METIL-5-(3-TRIFLUOROMETIL-BENZOILAMINO)-FENIL]-AMIDA; ACIDO 2-(2-HIDROXI-ETILAMINO)-TIAZOL-5-CARBOXILICO{5-[3-(4-ETIL-PIPERAZI-1-NIL)-5-TRIFLUOROMETIL-BENZOILAMINO]-2-METIL-FENIL}-AMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE QUINASAS PROTEICAS TALES COMO QUINASA DE TIROSINA ABELSON (Abl), QUINASA DE TIROSINA ONCOGENICA (BCR-Abl), ENTRE OTRAS; SIENDO UTILES EN EL TRATAMIENTO DE LEUCEMIAS, GLIOMAS, SARCOMAS, TROMBOSIS, PSORIASIS
PE2006000097A 2005-01-26 2006-01-23 Compuestos y composiciones como inhibidores de la kinasa proteica PE20060877A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64760605P 2005-01-26 2005-01-26

Publications (1)

Publication Number Publication Date
PE20060877A1 true PE20060877A1 (es) 2006-10-16

Family

ID=36740973

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000097A PE20060877A1 (es) 2005-01-26 2006-01-23 Compuestos y composiciones como inhibidores de la kinasa proteica

Country Status (15)

Country Link
US (1) US20090105250A1 (es)
EP (1) EP1841431A4 (es)
JP (1) JP2008528585A (es)
KR (1) KR100919905B1 (es)
CN (1) CN101106990B (es)
AR (1) AR052887A1 (es)
AU (1) AU2006209183B2 (es)
BR (1) BRPI0607307A2 (es)
CA (1) CA2593803A1 (es)
GT (1) GT200600028A (es)
MX (1) MX2007008973A (es)
PE (1) PE20060877A1 (es)
RU (1) RU2368602C2 (es)
TW (1) TW200637547A (es)
WO (1) WO2006081172A2 (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
JP5275628B2 (ja) 2004-08-25 2013-08-28 ターゲジェン インコーポレーティッド 複素環式化合物および使用方法
PE20061394A1 (es) * 2005-03-15 2006-12-15 Bristol Myers Squibb Co Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas
US20080207572A1 (en) * 2005-07-14 2008-08-28 Ab Science Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma
ATE539748T1 (de) * 2006-01-27 2012-01-15 Array Biopharma Inc Glucokinaseaktivatoren
CA2662580C (en) * 2006-09-11 2013-05-21 Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety
AU2007314305B2 (en) 2006-10-31 2013-01-24 Merck Sharp & Dohme Corp. 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors
AU2007314342B2 (en) 2006-10-31 2013-02-21 Merck Sharp & Dohme Corp. Anilinopiperazine Derivatives and methods of use thereof
US20110003809A1 (en) * 2008-02-29 2011-01-06 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
KR20100122505A (ko) * 2008-02-29 2010-11-22 어레이 바이오파마 인크. Ｒａｆ 저해물질 화합물 및 이들의 이용 방법
WO2009111279A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Pyrazole [3, 4-b] pyridine raf inhibitors
JP2011513332A (ja) * 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド 癌の治療のためのｒａｆ阻害剤としてのｎ−（６−アミノピリジン−３−イル）−３−（スルホンアミド）ベンズアミド誘導体
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
JO3101B1 (ar) * 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
EP2440058A4 (en) 2009-06-12 2012-11-21 Dana Farber Cancer Inst Inc MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF
CA2784807C (en) 2009-12-29 2021-12-14 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
EP2576566B1 (en) 2010-05-28 2015-10-28 Merck Sharp & Dohme B.V. Thieno(2,3b)pyrazine compounds as b-raf inhibitors
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
RU2011122942A (ru) * 2011-06-08 2012-12-20 Общество С Ограниченной Ответственностью "Асинэкс Медхим" Новые ингибиторы киназ
WO2013066483A1 (en) * 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
WO2013074986A1 (en) 2011-11-17 2013-05-23 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
RU2495430C1 (ru) * 2012-03-29 2013-10-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная академия" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО АГМА Минздравсоцразвития России) Способ оценки эффективности терапии хронического миелолейкоза
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
RU2495427C1 (ru) * 2012-07-04 2013-10-10 Федеральное бюджетное учреждение науки "Уфимский научно-исследовательский институт медицины труда и экологии человека" Способ прогнозирования ответа на химиотерапию при хроническом лимфолейкозе
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
WO2014069434A1 (ja) * 2012-10-30 2014-05-08 カルナバイオサイエンス株式会社 新規チアゾリジノン誘導体
HUE042591T2 (hu) 2013-02-19 2019-07-29 Ono Pharmaceutical Co TRK-gátló vegyület
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
AU2014361798B2 (en) 2013-12-13 2020-06-11 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9908872B2 (en) 2013-12-13 2018-03-06 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
EP3715346B1 (en) 2014-10-22 2024-01-03 Dana-Farber Cancer Institute, Inc. Thiazolyl-containing compounds for treating proliferative diseases
EP3236959B1 (en) 2014-12-23 2025-09-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
JP7028766B2 (ja) 2015-09-09 2022-03-02 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼの阻害剤
TWI620748B (zh) * 2016-02-05 2018-04-11 National Health Research Institutes 氨基噻唑化合物及其用途
JP7624690B2 (ja) 2016-03-01 2025-01-31 プロペロン セラピューティクス インコーポレイテッド Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
CA3015417A1 (en) 2016-03-01 2017-09-08 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
WO2018183122A1 (en) * 2017-03-27 2018-10-04 Sidecar Therapeutics, Inc. Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds
WO2019202160A2 (en) 2018-04-20 2019-10-24 Iomx Therapeutics Ag A 5-thiazolecarboxamide kinase inhibitor and uses thereof
EP3778577B1 (en) * 2018-05-09 2023-08-30 Lg Chem, Ltd. Novel compound exhibiting enteropeptidase inhibitory activity
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
EP3643713B1 (en) * 2018-10-23 2025-07-30 iOmx Therapeutics AG Heterocyclic kinase inhibitors and uses thereof
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
EP3901151A1 (en) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
TW202523302A (zh) 2023-11-02 2025-06-16 美商阿克思生物科學有限公司 噻唑化合物及其使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100282A (en) * 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
EP2308833A3 (en) * 1999-04-15 2011-09-28 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
ES2349532T3 (es) * 2003-02-06 2011-01-04 Bristol-Myers Squibb Company Compuestos basados en tiazolilo útiles como inhibidores de cinasa.

Also Published As

Publication number Publication date
MX2007008973A (es) 2007-09-18
TW200637547A (en) 2006-11-01
KR20070095978A (ko) 2007-10-01
CN101106990B (zh) 2010-12-08
AU2006209183A1 (en) 2006-08-03
BRPI0607307A2 (pt) 2009-08-25
WO2006081172A2 (en) 2006-08-03
CA2593803A1 (en) 2006-08-03
CN101106990A (zh) 2008-01-16
GT200600028A (es) 2006-10-18
EP1841431A2 (en) 2007-10-10
AU2006209183B2 (en) 2009-11-19
KR100919905B1 (ko) 2009-10-06
US20090105250A1 (en) 2009-04-23
EP1841431A4 (en) 2009-12-09
WO2006081172A3 (en) 2006-09-14
AR052887A1 (es) 2007-04-11
RU2007132262A (ru) 2009-03-10
RU2368602C2 (ru) 2009-09-27
JP2008528585A (ja) 2008-07-31

Similar Documents

Publication Publication Date Title
PE20060877A1 (es) Compuestos y composiciones como inhibidores de la kinasa proteica
PE20080538A1 (es) Derivado heterociclico fusionado y su uso
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20081120A1 (es) Derivados de hidantoina como inhibidores de metaloproteinasas de matriz (mmp)
PE20080074A1 (es) Derivados de amida como agentes inhibidores de la quinasa c-fms
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20090815A1 (es) Compuesto de amida
PE20081636A1 (es) Inhibidores de antranilamida para aurora quinasa
PE20060215A1 (es) 4-fenilamino-quinazolin-6-il-amidas
PE20050948A1 (es) Compuestos de carbamoil-amina como inhibidores de la dipeptidil peptidasa iv
PE20091486A1 (es) Derivado de pirrolopirimidina como inhibidor de la enzima pi3k
PE20080059A1 (es) Quinazolinas para la inhibicion de pdk1
PE20081836A1 (es) Derivados de piperidina como inhibidores de la sintasa de acido graso
PE20070121A1 (es) 2,4-diamino-pirimidinas como inhibidores de aurora
NZ588652A (en) Carboxamide compounds for the treatment of metabolic disorders
PE20081265A1 (es) Compuestos de biaril eter urea como inhibidores de faah
EA201100944A1 (ru) Производные изоксазола, предназначенные для применения в качестве регуляторов роста растений
PE20090649A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20120690A1 (es) Derivados de 5-fluoropirimidinona
PE20081199A1 (es) Derivados de azacicloalcanos como inhibidores de estearoil-coenzima a delta-9 desaturasa
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
PE20091458A1 (es) Compuestos heterociclicos antiviricos
PE20081487A1 (es) DERIVADOS DE NICOTINAMIDA COMO INHIBIDORES DE 11ßHSD1
PE20110598A1 (es) Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
NO20083514L (no) Heterobicykliske sulfonamidderivater for behandling av diabetes

Legal Events

Date Code Title Description
FC Refusal